QUESTRAN LIGHT Drug Patent Profile
When do Questran Light patents expire, and what generic alternatives are available?
Questran Light is a drug marketed by Bristol Myers and is included in one NDA.
The generic ingredient in QUESTRAN LIGHT is cholestyramine. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the cholestyramine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Questran Light
A generic version of QUESTRAN LIGHT was approved as cholestyramine by EPIC PHARMA LLC on August 15th, 1996.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for QUESTRAN LIGHT?
- What are the global sales for QUESTRAN LIGHT?
- What is Average Wholesale Price for QUESTRAN LIGHT?
Summary for QUESTRAN LIGHT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 9 |
| DailyMed Link: | QUESTRAN LIGHT at DailyMed |
Recent Clinical Trials for QUESTRAN LIGHT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Centre Hospitalier Universitaire de Nice | N/A |
| City of Hope Medical Center | Phase 1 |
| National Cancer Institute (NCI) | Phase 1 |
US Patents and Regulatory Information for QUESTRAN LIGHT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers | QUESTRAN LIGHT | cholestyramine | POWDER;ORAL | 019669-001 | Dec 5, 1988 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bristol Myers | QUESTRAN LIGHT | cholestyramine | POWDER;ORAL | 019669-003 | Dec 5, 1988 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Questran Light Market Dynamics, Patent Status, Competition, and Financial Trajectory
Questran Light is a mature prescription formulation of cholestyramine, a nonabsorbed bile-acid sequestrant used primarily to reduce elevated LDL cholesterol and relieve pruritus associated with partial biliary obstruction. Its commercial profile is defined by generic competition, low technological barriers, limited patent protection, and declining relevance in the modern lipid-lowering market.
The product has residual demand because it is inexpensive, orally administered, and clinically useful when statins or newer lipid therapies are unsuitable. Its revenue opportunity is limited by generic substitution, weak pricing power, an aging patient population, and competition from statins, ezetimibe, PCSK9 inhibitors, and other lipid-lowering therapies.
What is Questran Light and how is it used?
Questran Light contains cholestyramine, an anion-exchange resin that binds bile acids in the gastrointestinal tract. The resulting reduction in bile-acid reabsorption increases hepatic conversion of cholesterol into bile acids and can reduce circulating LDL cholesterol.[1]
| Product attribute | Questran Light profile |
|---|---|
| Active ingredient | Cholestyramine |
| Dosage form | Powder for oral suspension |
| Typical labeled strength | 4 grams of cholestyramine resin per dose |
| Administration | Mixed with water or another suitable liquid |
| Primary lipid indication | Adjunctive treatment for hypercholesterolemia |
| Other labeled use | Relief of pruritus associated with partial biliary obstruction |
| Absorption | Not systemically absorbed |
| Regulatory category | Prescription drug |
| Primary competitors | Generic cholestyramine powder, Questran, statins, ezetimibe and other lipid therapies |
The formulation is administered orally as a powder rather than a tablet or capsule. This reduces manufacturing complexity but creates adherence problems because patients must mix the product and may object to its texture or taste. Cholestyramine can also interfere with absorption of other medicines, requiring dose separation under the prescribing information.[1]
When does Questran Light lose exclusivity?
Questran Light has no meaningful remaining regulatory exclusivity based on its age and the availability of generic cholestyramine products. Cholestyramine was approved decades ago, placing the product outside the practical protection period for new chemical entities and conventional drug exclusivity.
The commercial protection profile is as follows:
| Protection category | Questran Light status |
|---|---|
| New chemical entity exclusivity | Expired |
| Orphan-drug exclusivity | Not applicable |
| Pediatric exclusivity | No commercially relevant current protection identified |
| Formulation exclusivity | Expired or commercially ineffective |
| Orange Book patent barrier | No meaningful current barrier generally associated with the product |
| Generic substitution | Established |
| Biosimilar protection | Not applicable |
The product’s active ingredient is an established nonbiologic drug. Biosimilar rules therefore do not apply. Market entry occurs through abbreviated new drug applications, not through the biosimilar pathway.
What patents protect Questran Light?
The core composition and therapeutic use of Questran Light are not protected by an active modern patent estate. Any historical patents covering cholestyramine, older formulations, manufacturing processes, or early therapeutic uses have expired or do not prevent generic competition.
Potentially relevant intellectual-property categories include:
- Cholestyramine resin composition.
- Particle-size and purification parameters.
- Flavoring and palatability systems.
- Sachet and packaging configurations.
- Methods for treating hypercholesterolemia.
- Methods for treating cholestatic pruritus.
- Manufacturing controls for resin consistency and microbial quality.
These categories do not create a material barrier to generic cholestyramine powder. A formulation patent would need to cover a technically distinct and commercially important feature that generic manufacturers could not readily design around. Questran Light’s conventional powder format offers limited scope for such protection.
Are formulation patents important for Questran Light?
Formulation patents have limited commercial value for Questran Light because the product’s basic dosage form is simple. Generic manufacturers can generally develop equivalent powder-for-suspension products using established cholestyramine resin technology.
The strongest potential differentiators are not patent-driven. They are:
- Flavor and tolerability.
- Dose uniformity.
- Dispersion in liquid.
- Packaging convenience.
- Supply reliability.
- Payer and pharmacy substitution status.
These attributes may influence prescribing and purchasing but do not normally support durable premium pricing.
What is the FDA regulatory and Orange Book status of Questran Light?
Questran Light is regulated as a prescription drug. Its labeling covers cholestyramine powder for oral suspension and includes warnings concerning gastrointestinal effects, drug-binding interactions, and the need to administer other medicines separately when appropriate.[1]
The FDA Orange Book is relevant because it identifies approved reference-listed drugs and therapeutically equivalent generic products. For a mature product such as Questran Light, the key commercial issue is whether generic cholestyramine products are rated therapeutically equivalent and available through normal pharmacy channels.[2]
The practical regulatory position is:
| FDA issue | Commercial effect |
|---|---|
| Reference-listed drug status | Supports approval of generic equivalents |
| Abbreviated new drug applications | Main route for generic competition |
| Therapeutic equivalence ratings | Facilitate pharmacy substitution where applicable |
| REMS requirement | No major REMS barrier associated with ordinary use |
| Biologic licensing | Not applicable |
| New clinical-trial requirement | Generally not required for standard generic entry |
The label’s clinical limitations also constrain growth. Cholestyramine is not a preferred first-line therapy for most patients with hypercholesterolemia because statins have stronger outcome evidence, simpler administration, and better routine adherence.
How many companies compete with Questran Light?
Competition exists at two levels: generic cholestyramine manufacturers and alternative lipid-lowering therapies.
Generic cholestyramine competition
Generic products may be marketed as cholestyramine powder for oral suspension, with multiple manufacturers or private-label suppliers participating over time. The number of active suppliers can change because the market is small and vulnerable to manufacturing interruptions.
Generic competition typically produces:
- Low average selling prices.
- Limited brand loyalty.
- Pharmacy-level substitution.
- Contracting with wholesalers and group purchasing organizations.
- Periodic shortages when a small number of facilities supply most demand.
The brand retains value mainly where prescribers or patients prefer the branded flavor, packaging, or supply consistency.
Therapeutic competition
| Therapy class | Relative position versus Questran Light |
|---|---|
| Statins | Stronger clinical evidence, lower routine cost, easier administration |
| Ezetimibe | Oral tablet, generally better tolerated and simpler to use |
| PCSK9 inhibitors | Much stronger LDL reduction but substantially higher cost |
| Bempedoic acid | Oral alternative for selected statin-intolerant patients |
| Fibrates | Used mainly for triglyceride-focused treatment |
| Other bile-acid sequestrants | Colesevelam and colestipol offer alternative resin-based approaches |
Questran Light can remain relevant for selected patients who cannot tolerate statins, require nonabsorbed therapy, or need treatment for cholestatic pruritus. Its role is narrower than its historical role in cholesterol management.
What is the financial trajectory of Questran Light?
Public companies generally do not disclose standalone revenue for Questran Light. The product is typically included within broader portfolios of mature prescription products, making brand-specific sales, gross margin, and unit data unavailable in standard company filings.
The financial trajectory is best characterized as mature and structurally declining, with possible periods of temporary stabilization. The main drivers are:
- Generic substitution and price erosion.
- Reduced use of bile-acid sequestrants for routine cholesterol treatment.
- Competition from inexpensive oral alternatives.
- Limited physician demand for powder formulations.
- Low promotional investment.
- Occasional supply constraints that can increase short-term volume or pricing.
A simplified commercial lifecycle is:
| Period | Market condition | Financial implication |
|---|---|---|
| Original launch period | Limited alternatives for cholesterol reduction | Premium brand economics |
| Generic-entry period | Multiple cholestyramine suppliers | Rapid price and share erosion |
| Mature market | Low-cost, low-promotion product | Stable niche demand |
| Current market | Narrow clinical use and intense substitution | Low growth, limited pricing power |
Questran Light can generate dependable cash flow if manufacturing costs are controlled and supply remains reliable. It is unlikely to produce material revenue growth without a new indication, improved delivery system, or acquisition by a company with a broader gastrointestinal or lipid portfolio.
What generic entry risks exist for Questran Light?
Generic entry risk is already realized rather than prospective. The principal commercial risk is continued substitution by generic cholestyramine powder, not a future Paragraph IV event against a valuable branded patent.
A generic manufacturer could challenge any remaining listed patent through a Paragraph IV certification if an applicable patent existed. In the present commercial context, such a challenge would have limited strategic value because the product is already a mature generic market and the underlying active ingredient has long been off patent.[2]
More important risks include:
- A wholesaler shifting volume to a lower-cost supplier.
- Pharmacy substitution away from the brand.
- Product discontinuation by a small manufacturer.
- Manufacturing-site disruption.
- Raw-material or resin-quality problems.
- Labeling or packaging changes that reduce prescribing continuity.
The risk of a large, sudden generic launch event is low because generic competition is already established. The risk of incremental share and price loss remains high.
What patent litigation and settlement agreements affect Questran Light?
No major current patent litigation or settlement agreement is associated with Questran Light’s core commercial position in the public record commonly used for FDA-listed drug and patent analysis.
This differs from newer branded drugs, where Paragraph IV litigation, launch-at-risk decisions, and patent settlements can determine billions of dollars in revenue. For Questran Light, litigation economics are unfavorable because:
- The underlying molecule is old.
- Generic products are available.
- The addressable market is modest.
- The dosage form is technically conventional.
- A successful injunction would have limited long-term value.
Any dispute is more likely to concern supply, trade dress, contract manufacturing, labeling, or commercial distribution than core patent exclusivity.
How strong is the Questran Light patent estate?
The patent estate is weak from a revenue-protection perspective.
| Patent-estate factor | Assessment |
|---|---|
| Active composition patents | No meaningful protection |
| Active method-of-use patents | No material barrier identified |
| Formulation differentiation | Limited |
| Manufacturing complexity | Moderate but reproducible |
| Generic design-around risk | High |
| Litigation leverage | Low |
| Pricing power | Low |
| Protection of future sales | Minimal |
Manufacturing know-how may still have value. Cholestyramine resin must meet quality, particle-size, stability, and purity specifications. Those requirements can create operational barriers, particularly for small suppliers. They do not normally create durable exclusivity because competing manufacturers can develop equivalent processes.
How does Questran Light compare with colesevelam?
Colesevelam is a later-generation bile-acid sequestrant with a more convenient solid oral dosage form and a different tolerability profile. Questran Light has the advantage of low cost and long clinical familiarity, while colesevelam offers easier administration but generally carries a higher price.
| Factor | Questran Light | Colesevelam |
|---|---|---|
| Form | Powder mixed with liquid | Tablets or suspension, depending on product |
| Generic pressure | High | Established, depending on market |
| Administration burden | High | Generally lower |
| Pricing power | Low | Historically higher |
| Primary commercial use | Niche lipid and pruritus treatment | Lipid management and selected metabolic uses |
| Patent value | Minimal | More recent historical protection, now reduced by generic entry |
Questran Light is more exposed to commodity-style pricing. Colesevelam has had greater formulation and indication differentiation, although generic competition has also weakened its economics.
What generic launch scenarios exist?
The most likely scenarios are:
Scenario 1: Continued low-price generic supply
Generic cholestyramine remains available from several suppliers. Questran Light retains a small branded niche based on familiarity, flavor, or patient preference. Revenue declines gradually.
Scenario 2: Supplier consolidation
One or more manufacturers exit the market. Remaining suppliers gain temporary volume and may raise prices. The brand could benefit if it maintains supply, but the effect would likely be episodic.
Scenario 3: Brand discontinuation
The owner exits because sales do not justify regulatory, manufacturing, and distribution costs. Generic cholestyramine continues to serve most demand.
Scenario 4: Product repositioning
An owner invests in improved palatability, convenient sachets, or a new delivery format. This could support a premium niche, but the investment would face limited market size and weak patent protection.
The base case is continued maturity, low growth, and gradual erosion rather than a major rebound.
What is the commercial outlook for Questran Light?
Questran Light has a defensive niche rather than a growth profile. Its commercial value depends on dependable supply, cost control, and retention of patients who need cholestyramine despite its administration burden.
The principal upside is temporary supply scarcity or a focused repositioning for cholestatic pruritus and selected statin-intolerant patients. The principal downside is further generic commoditization and declining use in hypercholesterolemia as clinicians adopt better tolerated and more convenient therapies.
Key Takeaways
- Questran Light is a mature cholestyramine powder product with no meaningful new-drug exclusivity remaining.
- Generic cholestyramine competition is established and is the main source of price pressure.
- The product has no material biosimilar risk because it is a conventional nonbiologic drug.
- Its patent estate is weak, and formulation or manufacturing know-how does not create durable market exclusivity.
- Public filings generally do not disclose standalone Questran Light revenue.
- The financial trajectory is low-growth to declining, with occasional supply-driven volatility.
- Its remaining value is concentrated in low cost, clinical familiarity, nonabsorbed therapy, and use in selected pruritus or lipid-management patients.
- Statins, ezetimibe, colesevelam, PCSK9 inhibitors, and other therapies limit expansion.
- Future generic risk is incremental rather than event-driven because generic competition already exists.
FAQs
Is Questran Light still available by prescription?
Availability can vary by supplier and market. The product category remains represented by cholestyramine powder for oral suspension, including generic versions.
Is Questran Light interchangeable with generic cholestyramine?
Generic substitution depends on the specific FDA therapeutic-equivalence designation, state pharmacy law, payer policy, and product availability. Pharmacists generally use the applicable FDA equivalence listing and prescription requirements.
Does Questran Light lower LDL cholesterol?
Yes. Cholestyramine can lower LDL cholesterol by binding bile acids in the intestine. It does not provide the same administration convenience or clinical positioning as modern first-line lipid therapies.
Can Questran Light be used for itching caused by liver disease?
The prescribing information includes relief of pruritus associated with partial biliary obstruction. Clinical use should follow the product label and physician direction.[1]
Is Questran Light a viable target for pharmaceutical licensing?
The product is more suitable for a low-cost portfolio, supply-resilience strategy, or niche gastrointestinal and hepatobiliary platform than for a growth-oriented licensing transaction. Its low price, generic competition, and limited patent protection constrain licensing economics.
References
- DailyMed. (n.d.). Questran Light: Cholestyramine powder, for suspension prescribing information. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.
- National Library of Medicine. (n.d.). Cholestyramine drug information. MedlinePlus.
- Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082-e1143.
More… ↓
